Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 6/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.52 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.52 |
| ▸ | LPL | P06858 | 5/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872211 | 0.87 | AGTR1 (0.50) | AGTR1AGTR2GP6 | |
| SCHEMBL21083902 | 0.82 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL18003201 | 0.82 | AGTR1 (0.61) | AGTR1AGTR2GP6 | |
| SCHEMBL8260372 | 0.80 | LPL (0.49) | AGTR1AGTR2LPLLIPG | |
| SCHEMBL28517678 | 0.80 | AGTR1 (0.59) | AGTR1AGTR2GP6 | |
| SCHEMBL4639444 | 0.80 | AGTR1 (0.59) | AGTR1AGTR2GP6 | |
| SCHEMBL8568897 | 0.80 | AGTR1 (0.59) | AGTR1AGTR2GP6 | |
| SCHEMBL965839 | 0.80 | AGTR1 (0.67) | AGTR1AGTR2GP6 | |
| SCHEMBL8638896 | 0.79 | AGTR1 (0.58) | AGTR1AGTR2GP6 | |
| SCHEMBL649 | 0.78 | AGTR1 (0.58) | AGTR1AGTR2GP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833801-B9 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2009-02-25 | — | — | EP | claimed |
| EP-1833801-B1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2008-06-04 | — | — | EP | claimed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-11407733-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-09 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
| EP-1833801-B9 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2009-02-25 | — | — | EP | disclosed |
| EP-1833801-B1 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA S L (ES) | 2008-06-04 | — | — | EP | disclosed |
| EP-1833801-A2 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUIMICA, S.L (ES) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006067215-A2 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR ANTAGONISTS | ALGRY QUÍMICA, S. L. (ES) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407733-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | AGTR1 7/4885AGTR2 6/4885GP6 2840/4885 |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | AGTR1 7/4885AGTR2 6/4885GP6 2840/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | AGTR1 7/4885AGTR2 6/4885GP6 2840/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | AGTR1 7/4885AGTR2 6/4885GP6 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.